🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsTirzepatide (Mounjaro / Zepbound)Mounjaro pen vs compounded vial - pros and cons?

Mounjaro pen vs compounded vial - pros and cons?

MounjBrad Sun, Apr 5, 2026 at 9:57 AM 4 replies 617 viewsPage 1 of 1
MounjBrad
Member
278
890
Oct 2024
Kentucky
Apr 5, 2026 at 9:57 AM#1

My pharmacy stopped supplying with three weeks notice and a letter that explained nothing, so I went and read the statute.

The bit I cannot resolve on my own is what actually distinguishes 503A from 503B, in terms of what each may make and from what starting material.

Tell me what I have not thought of.

5 0patPC_UT, Dr.DermMIA, fiona_VT and 2 others
Reply Quote Save Share Report
Dr.ObesityMed
VIP Member
3,456
19,234
Nov 2023
Denver, CO
Online
Apr 5, 2026 at 10:14 AM#2

Taking the question as asked, rather than the general version of it. The shortage clause is the answer to the second question and it is a subtraction rather than an addition. Both exemptions forbid compounding something that is essentially a copy of a commercially available approved product. A product FDA has listed as in shortage is not treated as commercially available, so listing removed the objection that otherwise blocked compounding. It never created a permission; it withdrew a prohibition, which is why it evaporated the moment the supply fact changed.

Last edited: Apr 5, 2026 at 4:14 PM
4 24PharmacoVig_BOS, SurmountFan_IN, PeptideChemSF and 1 other
Reply Quote Save Share Report
stefan_berlin
Member
234
1,123
Oct 2024
Berlin, DE
Apr 5, 2026 at 10:31 AM#3
Dr.ObesityMed said:
The shortage clause is the answer to the second question and it is a subtraction rather than an addition.

Agreed, and the enforcement dates were staggered by category — 503A first, 503B a few weeks later — because outsourcing facilities have manufactured inventory and clinic contracts to unwind while a 503A makes to order.

Last edited: Apr 5, 2026 at 1:31 PM
3 23KevinCompounds, TirzTom, TrialTracker_MD
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
Dr.RheumBOS
Member
567
2,345
Apr 2024
Boston, MA
Apr 5, 2026 at 10:48 AM#4
MounjBrad said:
My pharmacy stopped supplying with three weeks notice and a letter that explained nothing, so I went and read the statute.

Can confirm the pattern MounjBrad describes. They are two different exemptions from the same federal requirements and they buy different things. A 503A pharmacy is regulated primarily by the state board, needs a patient-specific prescription, is exempt from CGMP, and may use a bulk substance that has a USP monograph, is a component of an approved drug, or appears on the 503A bulks list — three independent doorways. A 503B outsourcing facility registers with the FDA, is inspected on a risk basis, must comply with CGMP, may compound for office stock without a patient-specific prescription, and has one doorway to a permitted bulk substance: the 503B bulks list, or the drug shortage list.

2 22lori_vegas, Dr.PulmRoch
Reply Quote Save Share Report
LindaRN_retired
Member
189
890
Dec 2024
Sarasota, FL
Apr 5, 2026 at 12:16 PM#5

From the other side of the consultation, briefly.

503A vs 503B compounding pharmacies for compounded supply — this distinction matters enormously:

Feature503A503B
RegulationState Board of PharmacyFDA-registered
PrescriptionRequired (patient-specific)Can compound without patient Rx
TestingVaries by statecGMP required
ScaleSmall batchesLarger production
Quality consistencyVariableGenerally higher

I strongly recommend 503B facilities. The FDA oversight and cGMP requirements mean more consistent product quality.

1 21mike_nyc
Reply Quote Save Share Report

Similar Threads

SURMOUNT-5: Tirzepatide vs semaglutide head-to-head — full results11 replies
SURPASS 1-5 program: tirzepatide T2DM efficacy data compilation6 replies
Tirzepatide dual agonism: GIP + GLP-1 synergistic mechanism18 replies
5mg → 10mg → 15mg titration — clinical guidance and real-world data8 replies
Zepbound insurance coverage — payer-by-payer breakdown 20268 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register